Inclusion Criteria:

- Subjects who have received at least one vaccine under protocol UPCC-19809 or
UPCC-29810.

- ECOG performance status 0 or 1.

- Subject has sufficient vaccine (2 vaccine doses are sufficient)

- Must be at least 4 weeks post-operative

- Blood coagulation parameters: PT such that international normalized ratio (INR) is
less than1.5 (or an in-range INR, usually between 2 and 3, if a subject is on a
stable dose of therapeutic warfarin for management of venous thrombosis including
pulmonary thromboembolus) and a PTT less than1.2 times the upper limit of normal.

- Subject must be 18 years of age or older.

- Life expectancy of greater than 4 months.

- Normal organ and bone marrow function as defined by: Absolute neutrophil count
greater than 1,000/microliter, Platelets greater than 100,000/microliter, Hematocrit
greater than 30%, AST (SGOT)/ALT(SGPT) less than 2.5 X institutional upper limit of
normal, Bilirubin less than 2.0 mg/dL unless secondary to bile duct blockage by
tumor, and Creatinine less than 1.8 mg/dL

Exclusion Criteria:

- Subjects who require or are likely to require more than a two-week course of
corticosteroids for intercurrent illness. Subjects must complete therapy prior to
enrollment. Topical corticosteroids should be stopped at least 2 weeks prior to
enrollment and systemic corticosteroids should be stopped at least 4 weeks prior to
enrollment.

- Subjects with any acute infection that requires specific therapy. Acute therapy must
have been completed at least seven days prior to study enrollment

- Subjects with any underlying conditions, which would contraindicate therapy with,
study treatment (or allergies to reagents used in this study).

- Subjects with prior history or symptoms suggestive of partial or complete bowel
obstruction.

- Subjects receiving class III antiarrythmic medications.

- Subjects receiving medications that might affect immune function. Additionally, H2
blockers are excluded, as are all antihistamines five days before and five days after
each injection of study drug. NOTE: The following are exceptions: Proton pump
Inhibitors (PPIs), NSAIDS including COX-2 inhibitors, acetaminophen.

- Subjects who are allergic to Aspirin are excluded

- Development of clinically significant co morbid disease that would contraindicate
study therapy or confuse interpretation of study results.

- Subjects with a History of bowel obstruction, including sub-occlusive disease,
related to the underlying disease and history of abdominal fistula, gastrointestinal
perforation or intra-abdominal abscess.

- Subjects with evidence of recto-sigmoid involvement by pelvic examination or bowel
involvement on CT scan or clinical symptoms of bowel obstruction.